Artal Group S.A.'s Form 4 filing
Crescent Biopharma, Inc. (CBIO) · filed Feb 28, 2023
- Accession no.
- 0000899243-23-006426
- Filed
- Feb 28, 2023, 5:33 PM ET
- Trade date
- Feb 24, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $170.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Artal Group S.A.CIK 0001053906 | 10% Owner |
| Artal International S.C.A.CIK 0001218180 | 10% Owner |
| Westend S.A.CIK 0001283968 | 10% Owner |
| Invus Public Equities Advisors, LLCCIK 0001340096 | 10% Owner |
| Invus Public Equities, L.P.CIK 0001340097 | 10% Owner |
| Stichting Administratiekantoor WestendCIK 0001460840 | 10% Owner |
| Artal International Management S.A.CIK 0001522131 | 10% Owner |
| Wittouck AmauryCIK 0001841311 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 24, 2023 | Common Stock | PPurchaseAcquired | +100,000 | $1.70 | +$170,000 | 8,589,064 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.